21 Jan Evotec International
Andreas Scheel, Ph.D., Executive Vice President, Head of Cell Therapy
April 28 | 3:00pm | Salone dei Cavalieri, Section 1
Hamburg, Germany
(NASDAQ : EVT)
Evotec is a leading life sciences company dedicated to delivering highly effective new therapeutics to patients. Leveraging multimodality platforms, we drive proprietary projects and co-create pipelines with partners across pharma, biotech, academia, and other healthcare stakeholders. Our flexible business model spans from service-based support to strategic partnerships. In cell therapy, Evotec offers one of the industry’s most comprehensive end-to-end platforms for advancing iPSC-based projects from inception to clinic. This includes in-house GMP manufacturing and GMP gene-editing capabilities. We focus on indications requiring long-term cell engraftment, such as regenerative therapies (beta cells, cardiomyocytes, photoreceptors) and immune-modulation therapies (macrophages). Additionally, Evotec provides integrated drug development solutions, covering safety assessment, CMC, process and analytical development, regulatory strategy, and clinical services for both autologous and allogeneic cell therapy candidates.
